Abstract:BackgroundAlpha fetoprotein (AFP) is a circulating tumor marker utilized clinically to detect liver cirrhosis, liver cancer and testicular seminomas. AFP molecule contains one single N-glycosylation site, with highly variable glycan structures, resulting in diverse AFP glycoforms in circulating blood. The core fucosylation of AFP (AFP-L3) is a clinical biomarker to monitor and predict risks of liver cancer progression and recurrence. Clinical testing for AFP-L3 utilizes lectin-binding and gel-shift electrophoresis. We developed a novel method to measure AFP glycoforms, based on immune-enrichment and liquid chromatography with high resolution mass spectrometry (LC-HRMS).MethodsImmune enrichment of AFP was achieved by anti-AFP antibody, immobilized to magnetic beads. After binding and enrichment, the magnetic beads were washed, AFP was eluted, and the samples were analyzed by LC-HRMS (Exploris 480 MS and Vanquish UHPLC, Thermo Fisher Scientific), using full scan, positive polarity acquisition mode. Chromatographic separation was performed on PLRP column (Agilent); flow rate 200 μL/min. The HRMS data were processed and deconvoluted with intact mass analysis workflow in Biopharma Finder 5.1 (Thermo Fisher Scientific) to derive the intact AFP masses. The method's sensitivity and imprecision were assessed by replicate analysis of serial diluted patient serum samples. AFP and its associated glycoforms were matched and identified with an in-house developed bioinformatics workflow. The deconvoluted intact masses and the sum intensity of detected charged species for each AFP glycoform were used to quantify relative abundance of AFP glycoforms.ResultsThe method specificity for AFP was confirmed by bottom-up analysis after immune-enrichment with observed peptide sequence coverage over 35%. The recovery of the immune enrichment was shown to be independent of the AFP glycoform compositions. The identified AFP glycoforms and their relative abundance were consistent among replicates between AFP concentration 100 ng/mL and 5000 ng/mL. Analysis of authentic serum specimens from patients with different chronic liver diseases and liver cancer (n=102), revealed multiple complex biantennary branched AFP glycan modifications, with different numbers of terminal sialic acid and core fucose. Four AFP glycoforms were identified in over 60% patient samples with elevated AFP concentrations. Although occurring consistently, relative abundance of these AFP glycoforms varied significantly among patients. Assessment of the AFP fucosylation and sialylation features suggested that the two are orthogonal processes. Clinical correlations suggested that fewer terminal sialic acids were associated with impaired liver functions, while the fucosylation was linked to inflammatory responses and presence of liver malignancy. Strong linear correlation (Spearman's rs=0.952, N=35) was observed between AFP-L3% quantitated by the LC-HRMS method, and AFP-L3% determined by the lectin-binding based isotachophoresis assay (Wako Diagnostics). Discrepancies between the two methods were observed in specimens containing < 400 ng/mL of AFP, in which the LC-HRMS method detected only a single predominant glycoform.ConclusionsWe developed and evaluated the LC-HRMS method for profiling circulating AFP glycoforms in patients with chronic liver diseases and liver cancer. The detected AFP glycoforms and their relative abundance were used to establish glycan features, which can be further linked to cancer development, impaired liver function, and inflammation.

Identification and Analysis of Α1,6‐fucosylated Proteins in Human Normal Liver Tissues by a Target Glycoproteomic Approach

Characterization of Core-Fucosylated Glycoproteins from Human Normal Liver Tissues

Identification and Analysis of Altered Alpha 1,6-Fucosylated Glycoproteins Associated with Hepatocellular Carcinoma Metastasis

Comprehensive Mapping of Protein N-Glycosylation in Human Liver by Combining Hydrophilic Interaction Chromatography and Hydrazide Chemistry

Identification of N-glycosylation sites on secreted proteins of human hepatocellular carcinoma cells with a complementary proteomics approach.

Aberrant fucosylation of glycosphingolipids in human hepatocellular carcinoma tissues.

Alteration of Liver N-glycome in Patients with Hepatocellular Carcinoma

Lectin-based Glycoproteomics to Explore and Analyze Hepatocellular Carcinoma-Related Glycoprotein Markers.

Dsa Affinity Glycoproteome of Human Liver Tissue

Selective Isolation and Analysis of Glycoprotein Fractions and Their Glycomes from Hepatocellular Carcinoma Sera

Con A Affinity Glycoproteomics of Normal Human Liver Tissue

Heterogeneities of Site-Specific N-Glycosylation in HCC Tumors with Low and High AFP Concentrations

Analysis of Glycan-Related Genes Expression and Glycan Profiles in Mice with Liver Fibrosis.

Investigation on Glycosylation Patterns of Proteins from Human Liver Cancer Cell Lines Based on the Multiplexed Proteomics Technology

Comparative Glycoproteomics Based on Lectins Affinity Capture of N-linked Glycoproteins from Human Chang Liver Cells and MHCC97-H Cells.

Identification of N-glycosylation in Hepatocellular Carcinoma Patients' Serum with a Comparative Proteomic Approach.

B-149 Diverse glycosylation of circulating alpha fetoprotein in chronic liver diseases profiled by intact mass high resolution mass spectrometry

Discovery of Core-Fucosylated Glycopeptides As Diagnostic Biomarkers for Early HCC in Patients with NASH Cirrhosis Using LC- HCD-PRM-MS/MS

A precise approach in large scale core-fucosylated glycoprotein identification with low- and high-normalized collision energy.

GlycoPCT: Pressure Cycling Technology-Based Quantitative Glycoproteomics Reveals Distinctive N-Glycosylation in Human Liver Biopsy Samples of Nonalcoholic Fatty Liver Disease.

Core-Fucosylated Glycoproteomics Correlated with the Metastasis of Hepatoma